Eton Pharmaceuticals, Inc.

Note1 — Company Overview**

Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently hasseven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company hassix additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector.

Note2 — Liquidity Considerations

The Company believes its existing cash and cash equivalents of $17,420 as of* March 31, 2025* in addition to revenues from products will be sufficient to fund its operating expenses and capital expenditure requirements for at least the nexttwelve months from the date of filing of this quarterly report. This estimate is based on the Company’s current assumptions, including assumptions relating to estimated sales and its ability to manage spending. The Company could use its available capital resources sooner than currently expected. Accordingly, the Company could seek to obtain additional capital through equity financings, the issuance of debt or other arrangements. However, the Company cannot make assurances that it will be able to raise additional capital if needed or under acceptable terms. The sale of additional equity* may*dilute existing stockholders, and newly issued stock could contain senior rights and preferences compared to currently outstanding common shares. The Company’s existing debt obligation contains covenants and limits the Company’s ability to pay dividends or make other distributions to stockholders. If the Company experiences delays in product development or sales growth, obtaining regulatory approval for its other product candidates, or is unable to secure such additional financing, it might need to scale back operations.

Note3 — Summary of Significant Accounting Policies

Basis of Presentation

The Company has prepared the accompanying condensed financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”). Certain prior period amounts, have been reclassified to conform to current year presentation in the condensed financial statements and notes to financial statements and these reclassifications hadno impact to prior period condensed financial statements.

Unaudited Interim Financial Information

The accompanying interim condensed financial statements are unaudited and have been prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments necessary for the fair presentation of the Company’s financial position as of* March 31, 2025,and the results of its operations and its cash flows for the periods ended March 31, 2025and2024.* The financial data and other information disclosed in these notes related to thethree-month periods ended* March 31, 2025and2024* are also unaudited. The interim financial statements are condensed and generally donot repeat the disclosures in the annual financial statements. As such, the interim financial statements herein should be read in conjunction with the Company’s latest annual financial statements filed on Form10-K on* March 18, 2025.The results for thethree*-month periods ended* March 31, 2025arenot* necessarily indicative of results to be expected for the year ending* December 31, 2025,*any other interim periods, or any future year or period.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but arenot limited to, Medicaid program rebates, valuation of inventories, useful lives of assets and the recoverability of long-lived assets, valuation of deferred tax assets, and the valuation of common stock, stock options, warrants, and restricted stock units (“RSUs”). Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.

Acquisitions

The Company evaluates each of its acquisitions in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic805, Business Combinations (“ASC805”), to determine whether the transaction is a business combination or an asset acquisition. In determining whether an acquisition should be accounted for as a business combination or an asset acquisition, the Companyfirst performs a screening test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the acquired set isnot deemed to be a business and is instead accounted for as an asset acquisition. If this isnot the case, the Company then further evaluates whether the acquired set includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. If so, the Company concludes that the acquired set is a business.

The Company accounts for business acquisitions using the acquisition method of accounting. Under this method of accounting, assets acquired and liabilities assumed are recorded at their respective fair values at the date of the acquisition. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions. The Company’s estimates of fair value are based upon assumptions believed to be reasonable, but these assumptions are inherently uncertain and unpredictable and, as a result, actual results* may*differ from estimates. Any excess of the purchase price over the fair value of the net assets acquired is recognized as goodwill.

During the measurement period, which* maybe up toone* year from the acquisition date, the Company adjusts the provisional amounts of assets acquired and liabilities assumed with the corresponding offset to goodwill to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded within the Company’s consolidated statements of operations.

5

Segment Information

The Company operates the business on the basis of a single reportable segment, which includesseven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company derives revenues from product sales to specialty pharmacy customers, who then provide order fulfillment, inventory storage and distribution services. The Company’s chief operating decision-maker (“CODM”) is the Chief Executive Officer, who evaluates the Company’s financial performance and results of operations as a single operating segment. The CODM reviews net income or loss as a measure of segment profit or loss in assessing performance and allocating resources. Segment revenues, expenses and profit or loss is reported on the Condensed Statements of Operations. Additionally, the measure of segment assets is reported on the Company’s balance sheet as total assets.

The Company's revenues and its accounts receivable balances are highly concentrated and consist of sales to and amounts due from AnovoRx and Optime Care for the Company's INCRELEX®, ALKINDI SPRINKLE®, Carglumic Acid, GALZIN® and Betaine Anhydrous products, as well as from Pentec Heath for sales of the Company’s PKU GOLIKE® product. For thethree months ended* March 31, 2025and2024,* AnovoRx product sales represented 90.8% and 97.7% of net product revenues, respectively. As of* March 31, 2025and December 31, 2024**,* AnovoRx product sales represented 59.2% and 92.2% of net accounts receivable.

As of* March 31, 2025and December 31, 2024**,* all long-lived assets were domiciled within the U.S.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity ofthree months or less to be cash equivalents. All cash and cash equivalents are held in U.S. financial institutions or invested in high-grade money market funds. As of* March 31, 2025and December 31,** *2024, the Company’s cash is in a non-interest-bearing account and a high-grade money market fund. From time to time, amounts deposited with its bank exceed federally insured limits. The Company believes the associated credit risk to be minimal.

Accounts Receivable

Accounts receivable are recorded at the invoiced amount and are non-interest bearing. Accounts receivable are recorded net of allowances for credit losses, cash discounts for prompt payment, distribution fees, chargebacks and returns and allowances. The Company considers historical collection rates and the current financial status of its customers, as well as macroeconomic and industry-specific factors when evaluating potential credit losses. Historically, the Company's accounts receivable balances have been highly concentrated with a select number of customers, consisting primarily of specialty pharmacies and large wholesale pharmaceutical distributors. Given the size and creditworthiness of these customers, we havenot experienced and donot expect to experience material credit losses. The total for all accounts receivable reserves was $262 and $238 as of* March 31, 2025* and* December 31, 2024*, respectively.

Inventories

The Company values its inventories at the lower of cost or net realizable value using thefirst-in,first-out method of valuation. The Company reviews its inventories for potential excess or obsolete issues on an ongoing basis and records a write-down if an impairment is identified. As of* March 31, 2025* and* December 31, 2024*, inventories consisted of purchased finished goods, semi-finished goods and raw materials. At* March 31, 2025*, inventories are shown net of a reserve for Nitisinone, Betaine Anhydrous, GALZIN®, ALKINDI SPRINKLE® and PKU GOLIKE® inventory. As of* March 31, 2025and December 31, 2024,inventories included $5,000 in prepaid raw materials acquired in the INCRELEX® business acquisition as the Company will take title and possession to the raw materials on June 19, 2025.At December 31, 2024* inventories are shown net of a reserve for Nitisinone, Betaine Anhydrous, ALKINDI SPRINKLE® and PKU GOLIKE® inventory. There was an inventory reserve of $695 and $605 at* March 31, 2025* and* December 31, 2024*, respectively.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed utilizing the straight-line method based on the following estimated useful lives. Computer hardware and software is depreciated overthree years. Equipment, furniture and fixtures is depreciated over five years. Leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is shorter. Construction in progress is capitalized butnot depreciated until it is placed into service. Maintenance and repairs are charged to expense as incurred, while renewals and improvements are capitalized. Depreciation expense for thethree-month periods ended* March 31, 2025and2024* was $12 and $14, respectively.

Intangible Assets

The Company capitalizes payments it makes for licensed products when the payment is based on FDA approval for the product and the cost is recoverable based on expected future cash flows from the product. The cost is amortized on a straight-line basis over the estimated useful life of the product commencing on the approval date or the product acquisition date in accordance with ASC350 — Intangibles - Goodwill and Other. In* November 2021,the Company purchased the rights for its Carglumic Acid product for $3,250 and that cost is being amortized overten years. In September 2022,the Company purchased the rights for its Betaine Anhydrous product for $2,125 and that cost is being amortized over five years. In October 2023,the Company purchased the rights for its Nitisinone product for $650 and that cost is being amortized over five years. In March 2024**,* the Company purchased the rights for its PKU GOLIKE® product which resulted in a $1,868 intangible asset that is being amortized overten years. In* December 2024,the Company completed a business combination of INCRELEX® (mecasermin injection) that included a marketed product intangible of $21,250 and that cost is being amortized overten years. In December 2024,*the Company acquired GALZIN® (zinc acetate) for $8,119 and that cost is being amortized overten years.

6

The intangible assets, net on the Company’s Condensed Balance Sheet, reflected $3,382 and $2,381 of accumulated amortization as of* March 31, 2025* and* December 31, 2024*.The Company recorded $1,001 and $220, respectively, of amortization expense for thethree months ended* March 31, 2025and2024*, respectively. The table below shows the estimated remaining amortization for these products for each of thefive years from2025 to2029 and thereafter.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset* may**not* be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the Company’s Condensed Statements of Operations for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment was recognized during thethree-month periods ended* March 31, 2025or2024*.

Deferred Financing Costs, Debt Discount and Detachable Debt-Related Warrants

Costs incurred to issue debt are deferred and recorded as a reduction to the debt balance in the accompanying Condensed Balance Sheet. The Company amortizes these costs over the expected term of the related debt under the effective interest method. Debt discounts related to the relative fair value of warrants issued in conjunction with debt are also recorded as a reduction to the debt balance and accreted over the expected term into interest expense using the effective interested method.

Leases

The Company accounts for leases in accordance with ASC Topic842 — Leases. The Company reviews all relevant facts and circumstances of a contract to determine if it is a lease whereby the terms of the agreement convey the right to control the direct use and receive substantially all the economic benefits of an identified asset for a period of time in exchange for consideration. The associated right-of-use assets and lease liabilities are recognized at lease commencement. The Company measures lease liabilities based on the present value of the lease payments over the lease term discounted using the rate it would pay on a loan with the equivalent payments and term for the lease. The Company doesnot include the impact for lease term options that would extend or terminate the lease unless it is reasonably certain that it will exercise any such options. The Company accounts for the lease components separately from non-lease components for its operating leases.

The Company measures right-of-use assets based on the corresponding lease liabilities adjusted for (i) any prepayments made to the lessor at or before the commencement date, (ii) initial direct costs it incurs, and (iii) any incentives under the lease. In addition, the Company evaluates the recoverability of its right-of-use assets for possible impairment in accordance with its long-lived assets policy.

Operating leases are reflected on the Condensed Balance Sheet as operating lease right-of-use assets, current accrued liabilities and long-term operating lease liabilities. The Company doesnot have any finance leases as of* March 31, 2025* and* December 31, 2024*.

The Company commences recognizing operating lease expense when the lessor makes the underlying asset available for use by the Company and the operating lease expense is recognized on a straight-line basis over the term of the lease. Variable lease payments are expensed as incurred.

The Company doesnot recognize right-of-use assets or lease liabilities for leases with a term oftwelve months or less; such lease costs are recorded in the Condensed Statements of Operations on a straight-line basis over the lease term.

Patent Costs

All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the successful award of a patent and the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.

7

Concentrations of Credit Risk, Sources of Supply and Significant Customers

The Company is subject to credit risk for its cash and cash equivalents, which are invested in money market funds and U.S. treasury bills from time to time. The Company maintains its cash and cash equivalent balances withone major commercial bank and the deposits held with the financial institution exceed the amount of insurance provided on such deposits and is exposed to credit risk in the event of a default by the financial institutions holding its cash and cash equivalents to the extent recorded on the Condensed Balance Sheet. The Company believes the associated credit risk to be minimal.

The Company is dependent onthird-party suppliers for its products and product candidates. In particular, the Company relies, and expects to continue to rely, on a small number of suppliers to manufacture key chemicals, approved products and process its product candidates as part of its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process.

The Company is also subject to credit risk from its accounts receivable related to product sales as it extends credit based on an evaluation of the customer’s financial condition, and collateral isnot required. The Company's accounts receivables are evaluated to determine if any allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company's historical collection experience. Additionally, Management monitors its exposure to accounts receivable by periodically evaluating the collectability of the account receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and any prior customer credit loss experience. Based upon the review of these factors, the Company recordedno allowance for credit losses at* March 31, 2025* or* December 31, 2024*.

Revenue Recognition for Contracts with Customers

The Company accounts for contracts with its customers in accordance with ASC606 — Revenue from Contracts with Customers. ASC606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC606, the entity performs the followingfive steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

At contract inception, once the contract is determined to be within the scope of ASC606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses whether these options provide a material right to the customer and, if so, they are considered performance obligations. Renewal options that provide a material right are treated as a separate performance obligation, allocated a portion of the transaction price and related revenue is deferred until the option is exercised or the option expires unused.

The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time.

Milestone Payments– If a commercial contract arrangement includes development milestone payments, the Company will evaluate* whether the milestone conditions have been achieved and if it is probable that a significant revenue reversal wouldnot* occur before recognizing the associated revenue. Milestone payments that arenot within the Company’s control or the licensee’s control, such as regulatory approvals, are generallynot considered probable of being achieved until those approvals are received.

Licensing Revenues– The Company recognizes revenues from licensing arrangements primarily associated with product license agreements that could contain development activity milestones and agreements to divest the licensing rights to products or product candidates. At the inception of each licensing agreement, the Company assesses the goods or services promised within the contract to identify performance obligations. If a license to the Company's product rights is determined to be distinct from other promised goods or services, it is accounted for as a separate performance obligation. If a license grants the customer a right to use the Company's product license, revenue is recognized at the point in time when the license is transferred to the customer and the customer has the ability to use and benefit from the product license. Additionally, revenue is recognized from product license agreements with development activity milestones when these development activities occur per the contractual terms of the agreement.

Royalties– For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a* *customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.

Significant Financing Component– In determining the transaction price, the Company will adjust consideration for the effects of the time value of money if* the expected period between payment by the licensees and the transfer of the promised goods or services to the licensees will be more thanone* year.

The Company sells its INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone products to pharmacy distributor customers which provide order fulfilment and inventory storage/distribution services. The Company* maysell products in the U.S. to wholesale pharmaceutical distributors, who then sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual shipments represent performance obligations under each purchase order. The Company uses athird*-party logistics (“3PL”) vendor to process and fulfill orders and has concluded it is the principal in the sales to wholesalers because it controls access to the3PL vendor services rendered and directs the3PL vendor activities. The Company hasno significant obligations to wholesalers to generate pull-through sales.

8

For its INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone products, the Company bills at the initial product list price which are subject to offsets for patient co-pay assistance and potential state Medicaid reimbursements which are recorded as a reduction of net revenues at the date of sale/shipment. Selling prices initially billed to wholesalers* may*be subject to discounts for prompt payment and subsequent chargebacks when the wholesalers sell products at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs.

The Company estimates the transaction price when it receives each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler/distributor arising from all of the above factors. The Company has developed estimates for future returns and chargebacks and the impact of other discounts and fees it pays, although INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone sales arenot subject to returns.

The Company stores its INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone inventory at its pharmacy distributor customer locations, and sales are recorded when stock is pulled and shipped to fulfill specific patient orders. The Company* mayrecognize revenue and cost of sales from products sold to wholesalers upon delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership and have an enforceable obligation to pay the Company. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, the Company doesnot* believe they have a significant incentive to return the product.

Upon recognition of revenue from product sales, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, state Medicaid and GPO fees are included in sales reserves, accrued liabilities and net accounts receivable. The Company monitors actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts end up differing from its estimates, it will make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.

The state Medicaid rebate and related liability are estimated based on monthly sales, historical experience of claims submitted by the various states and jurisdictions, historical rebate rates and estimated lag time of the rebate invoices.

Cost of Sales

Cost of product sales consists of the profit-sharing and royalty fees with the Company’s product licensing and development partners, the purchase costs for finished products fromthird-party manufacturers, freight and handling/storage from the Company’s3PL logistics service providers, and amortization expense of certain intangible assets. The costs of sales for profit-sharing, royalty fees, purchased finished products, and the associated inbound freight expense are recorded when the associated product sale revenue is recognized in accordance with the terms of shipment to customers while outbound freight and handling/storage fees charged by the3PL service provider are expensed as they are incurred. Intangible assets are amortized on a straight-line basis over the estimated useful life of the product. Cost of product sales also reflects any write-downs or reserve adjustments for the Company’s inventories.

Licensing cost of sales* mayconsist of supply agreements and profit-sharing agreements associated with the Company’s sale of its product licenses to customers. The costs of sales for profit-sharing agreements are recognized upon the achievement of certain development and commercial milestones. For thethree* months ended* March 31, 2025,the Company recognized $825 in license cost of sales associated with the recognition of a development milestone related to the August 2024*sale of its DS-200 product candidate.

Research and Development Expenses

Research and development (“R&D”) expenses include both internal R&D activities and external contracted services. Internal R&D activity expenses include salaries, benefits and stock-based compensation and other costs to support the Company’s R&D operations. External contracted services include product development efforts such as certain product licensor milestone payments, clinical trial activities, manufacturing and control-related activities and regulatory costs. R&D expenses are charged to operations as incurred. The Company reviews and accrues R&D expenses based on services performed and* may,*from time to time, make estimates of those costs applicable as to the stage of completion of each project. Actual results could differ from the Company’s estimates.

Upfront payments and milestone payments made for the licensing of technology for products that arenot yet approved by the FDA are expensed as R&D in the period in which they are incurred. Nonrefundable advance payments for goods or services to be received in the future for use in R&D activities are recorded as prepaid expenses and are expensed as the related goods are delivered or the services are performed.

Income (Loss) Per Share

Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as unvested restricted stock, stock options and warrants that are outstanding during the period. Common stock equivalents are excluded from the computation when their inclusion would be anti-dilutive.No such adjustments were made for2025 or2024 as the Company reported a net loss for thethree months ended* March 31, 2025and2024* and including the effects of common stock equivalents in the diluted earnings per share calculation would have been anti-dilutive (see Note8).

9

Income Taxes

The Company accounts for income taxes under the provisions of ASC740 - Income Taxes. As part of the process of preparing the Company’s financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the Condensed Balance Sheet. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery isnot likely, a valuation allowance must be established. To the extent the Company establishes a valuation allowance or increase or decrease to this allowance in a period, the impact will be included in income tax expense in the Condensed Statements of Operations. As of* March 31, 2025* and* December 31, 2024*, the Company has established a 100% valuation reserve against its deferred tax assets. See Note9 for further information.

Stock-Based Compensation

The Company accounts for stock-based compensation under the provisions of ASC718 Compensation – Stock Compensation. The guidance under ASC718 requires companies to estimate the fair value of the stock-based compensation awards on the date of grant and record expense over the related service periods, which are generally the vesting period of the equity awards. Compensation expense is recognized over the period during which services are rendered by consultants and non-employees until completed.

The Company estimates the fair value of stock-based option awards using the Black-Scholes option-pricing model (“BSM”). The BSM requires the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate was determined from the implied yields forzero-coupon U.S. government issues with a remaining term approximating the expected life of the options or warrants. Dividends on common stock are assumed to bezero for the BSM valuation of the stock options. The expected term of stock options granted is based on vesting periods and the contractual life of the options. Expected volatilities are based on the Company's historical volatility subsequent to our IPO, which we believe represents the most accurate basis for estimating expected future volatility under the current conditions. The Company accounts for forfeitures as they occur.

Fair Value Measurements

We measure certain of our assets and liabilities at fair value. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value accounting requires characterization of the inputs used to measure fair value into athree-level fair value hierarchy as follows:

Level1** — Inputs based on quoted prices in active markets for identical assets or liabilities. An active market is a market in which transactions occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

*Level2 ***— Observable inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent from the entity.

*Level3 ***— Unobservable inputs that reflect the entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available.

Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which* may*affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below take into account the market for the Company’s financials, assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and debt obligation. The carrying amounts of these financial instruments approximate their fair values due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying value of the debt obligation approximates its fair value.

Impact of Recent Accounting Pronouncements

In* December 2023,the FASB issued ASU2023*-09, Income Taxes (Topic740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company's annual periods beginning* January 1, 2025,with early adoption permitted, and may*be applied either prospectively or retrospectively. The Company is assessing the guidance, noting the adoption impacts disclosure only.

In* November 2024,the FASB issued ASU2024*-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic220-40). Additionally, in* January 2025,the FASB issued ASU2025*-01 to clarify the effective date of ASU2024-03. The standard provides guidance to expand disclosures related to the disaggregation of income statement expenses. The standard requires, in the notes to the financial statements, disclosure of specified information about certain costs and expenses, which includes purchases of inventory, employee compensation, depreciation and intangible asset amortization included in each relevant expense caption. This guidance is effective for fiscal years beginning after* December 15, 2026,and interim periods within annual reporting periods beginning after December 15, 2027,*on a retrospective or prospective basis, with early adoption permitted. The Company is assessing the guidance, noting the adoption impacts disclosure only.

10

Note4 — Long-Term Debt

SWK Loan

In* November 2019,the Company entered into a credit agreement (the “SWK Credit Agreement”) with SWK, which provided $10,000 in debt financing. In March 2020and April 2022,the Company and SWK entered into amendments to the SWK Credit Agreement. In November 2019,the Company issued warrants to SWK to purchase 51,239 shares of the Company’s common stock with an exercise price of $5.86 per share. The relative fair value of these 51,239 warrants was $226 and was estimated using the Black-Scholes-Merton option pricing model with the following assumptions: fair value of the Company’s common stock at issuance of $5.75 per share; seven-year contractual term;95% volatility;0% dividend rate; and a risk-free interest rate of 1.8%. In August 2020,*the Company issued additional warrants for 18,141 shares of its common stock at an exercise price of $6.62 per share. The relative fair value of the 18,141 warrants was $94 and was estimated using the Black-Scholes-Merton option pricing model with the following assumptions: fair value of the Company’s common stock at issuance of $6.85 per share; seven-year contractual term;95% volatility;0% dividend rate; and a risk-free interest rate of 0.4%. These warrants (the “SWK Warrants”) are exercisable immediately and have a term ofseven years from the date of issuance. The SWK Warrants are subject to a cashless exercise feature, with the exercise price and number of shares issuable upon exercise subject to adjustment in connection with stock splits, dividends, reclassifications and other conditions.

In* September 2024,the Company and SWK entered into a subsequent amendment to the SWK Credit Agreement. Under the terms of the amendment, the Company expanded its existing credit facility by $25,700 to$30,000,* extended the facility’s maturity tothree years from closing with a loan maturity date of* December 17, 2027,and reduced the facility’s annual interest rate to Secured Overnight Financing Rate (“SOFR”) plus 6.75%. In connection with the amendment to the SWK Credit Agreement, the Company issued a warrant to the SWK for the purchase of up to 289,736 shares of common stock at a price of $5.32 per share. The relative fair value of these289,7369* warrants was $1,170 and was estimated using the BSM with the following assumptions: fair value of the Company’s common stock at issuance of $6.00 per share with an exercise price of$5.32; seven-year contractual term;63.8% volatility;0% dividend rate; and a risk-free interest rate of 3.67%.

Interest payments are payable quarterly, with quarterly principal payments of $3,000 beginning in* May 2026with a final principal payment of $9,000 due at maturity in December 2027.The amended SWK Credit Agreement includes a 5.0% exit fee payable at maturity and this exit fee payable will be accreted to interest expense in the Company's Condensed Statement of Operations using the effective interest expense method. The amended SWK Credit Agreement contains a mandatory prepayment clause that can compel the Company to partially prepay the loan upon certain triggering events, which the Company has deemed to be remote. Borrowing under the amended SWK Credit Agreement is secured by the Company's assets, contains customary default provisions, which include limits on additional indebtedness. As of March 31, 2025* and* December 31, 2024*, the Company was in compliance with all financial covenants.

The Company recorded interest expense of $1,163 and $238 for thethree months ended* March 31, 2025and2024,* respectively, which included $294 and $25, respectively of debt discount and non-cash interest expense. During thethree months ended* March 31, 2025,debt discount amortization and accrued exit fees was $56 and $126, respectively, associated with the SWK Credit Agreement and $112 was associated with interest expense accretion on the $5,000 deferred consideration due to Ipsen S.A (See Note12* for further discussion). As of* March 31, 2025and December 2024,*the Company had accrued interest of $409 and $182, respectively, which is included in accrued liabilities in the accompanying Condensed Balance Sheet.

The table below reflects the future payments for the SWK loan principal and interest as of* March 31, 2025*.

Note5 — Common Stock

The Company has 50,000,000 authorized shares of $0.001 par value common stock under its Amended and Restated Certificate of Incorporation.

During thethree months ended* March 31, 2025*, the Company issued 108,451 shares of its common stock resulting from stock option exercises under its2018 Equity Incentive Plan as amended in* December 2020.In March 31, 2024* the Company issued 2,500 shares of its common stock resulting from stock option exercises under its2018 Equity Incentive Plan.

11

Note6 — Common Stock Warrants

The Company’s outstanding warrants to purchase shares of its common stock at* March 31, 2025* are summarized in the table below.

The holders of these warrants or their permitted transferees, are entitled to rights with respect to the registration under the Securities Act of their shares that are converted to common stock, including demand registration rights and piggyback registration rights. These rights are provided under the terms of a registration rights agreement between the Company and the investors.

Note7 — Share-Based Payment Awards

The Company’s board of directors and stockholders approved the Eton Pharmaceuticals, Inc.2017 Equity Incentive Plan in* May 2017** (the“2017* Plan”), which authorized the issuance of up to 5,000,000 shares of the Company’s common stock. In conjunction with the Company’s IPO in* November 2018**,* the Company’s stockholders and board of directors approved the2018 Equity Incentive Plan, as amended (the*“2018* Plan”) which succeeded the2017 Plan. The Company has granted RSAs, stock options and RSUs for its common stock under the2017 Plan and2018 Plan as detailed in the tables below. There were 990,162 shares available for future issuance under the2018 Plan as of* March 31, 2025.*

Shares that are expired, terminated, surrendered or canceled without having been fully exercised will be available for future awards under the2018 Plan. In addition, the2018 Plan provides that commencing* January 1, 2019and through January 1, 2028,the share reserve will be increased by 4% of the total number of shares outstanding as of the preceding December 31,subject to a reduction at the discretion of the Company’s board of directors. On January 1, 2023,the share reserve was increased by 1,014,124 shares based on the 25,353,119 shares of common stock outstanding at December 31, 2022.On January 1, 2024,the share reserve was increased by 1,027,522 shares based on the 25,688,062 shares of common stock outstanding at December 31, 2023.On January 1, 2025,the share reserve was increased by 1,068,323 shares based on the 26,709,084 shares of common stock outstanding at December 31, 2024.The exercise price for stock options granted isnot* less than the fair value of common stock as determined by the board of directors as of the date of grant. The Company uses the closing stock price on the date of grant as the exercise price.

To date, all stock options issued have been non-qualified stock options, and the exercise prices were set at the fair value for the shares at the dates of grant. Options typically have aten-year life, except for options to purchase 50,000 shares of the Company’s common stock granted to product consultants in* July 2017that expired, unexercised, in July 2022as the Company wasnot* able to file certain product submissions to the FDA prior to thefive-year expiration date. Furthermore, these option awards to the Company’s product consultants wouldnot vest unless certain product submissions are made to the FDA, and accordingly, the Company hasnot recorded any expense for these contingently vesting option awards to its product consultants.

For thethree months ended* March 31, 2025and2024*, the Company’s total stock-based compensation expense was $1,200 and $821, respectively. Of these amounts, $1,161 and $742 were recorded in general and administrative (“G&A”) expenses during thethree months ended* March 31, 2025and2024,* respectively, and $39 and $79 were recorded in research and development expenses for thethree months ended* March 31, 2025and2024,* respectively.

Stock Options

The following table summarizes stock option activity during thethree months ended* March 31, 2025*:

12

Note7 — Share-Based Payment Awards (continued)**

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock at* March 31, 2025* for those stock options that had strike prices lower than the fair value of the Company’s common stock.

Stock based compensation related to stock options was $929 and $705 for thethree-month periods ended* March 31, 2025and2024*, respectively. As of* March 31, 2025*, there was a total of $7,546 of unrecognized compensation costs related to non-vested stock option awards. The weighted average grant date fair value of stock option awards for thethree months ended* March 31, 2025* was $8.35 per share. During thethree months ended* March 31, 2025,the Company issued 108,451 shares of its common stock resulting from stock option exercises at a weighted average exercise price of $3.63 per share with an intrinsic value of $1,167. During thethree* months ended* March 31, 2024,*the Company issued 2,500 shares of its stock resulting from stock option exercises at a weighted average exercise price of $2.97 per share with an intrinsic value of $2.

Restricted Stock Units (RSUs)

The following table summarizes restricted stock unit activity during thethree months ended* March 31, 2025*:

Stock-based compensation related to RSUs was $190 and $60 for thethree-month periods ended* March 31, 2025and2024*, respectively. As of* March 31, 2025*, there was $2,685 of unrecognized stock-based compensation expense related to unvested RSUs, which will be recognized over a weighted average period of approximately 2.8 years.

Employee Stock Purchase Plan

The Company’s2018 Employee Stock Purchase Plan (“ESPP”) provides for an initial reserve of 150,000 shares, and this reserve is automatically increased on* January 1of each year by the lesser of 1% of the outstanding common shares at December 31of the preceding year or 150,000 shares, subject to reduction at the discretion of the Company’s board of directors. As of March 31, 2025*, there were 842,581 shares available for issuance under the ESPP.

The annual offerings consist oftwo stock purchase periods, with thefirst purchase period ending in* Juneand thesecond* ending in* December.The terms of the ESPP permit employees of the Company to use payroll deductions to purchase stock at a price per share that is at least the lesser of (1)85% of the fair market value of a share of common stock on thefirst* date of an offering or (2)85% of the fair market value of a share of common stock on the date of purchase. After the offering period ends, subsequenttwelve-month offering periods automatically commence over the term of the ESPP on the day that immediately follows the conclusion of the preceding offering, each consisting oftwo purchase periods approximatelysix months in duration. The terms of the ESPP provide a restart feature if the Company's stock price is lower at the end of asix-month period within thetwelve-month offering period than it was at the beginning of thetwelve-month offering period.

For thethree-month periods ended* March 31, 2025and2024*, there wereno share issuance under the ESPP. The Company recorded an expense of $81 and $56 related to the ESPP during thethree-month periods ended* March 31, 2025and2024*, respectively. As of* March 31, 2025* and* December 31, 2024*, the accompanying Condensed Balance Sheet include $276 and $42, respectively, in accrued liabilities for employee ESPP contributions.

Note8 — Basic and Diluted Net Loss per Common Share

For thethree months ended* March 31, 2025,basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period and includes common stock equivalents (using the treasury stock and “if converted” method) from stock options, RSUs, and warrants. For thethree* months ended* March 31, 2025and2024,* 4,130,700 and 5,942,961, respectively, in common stock equivalents are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. During thethree months ended* March 31, 2025and2024,* included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director retires from service as a director.

The following table shows the computation of basic and diluted net loss per common share:

13

Note9 — Income Taxes

The following table summarizes the Company's income tax expense and effective tax rates for thethree months ended* March 31, 2025and2024:*

The Company's quarterly income tax provision is calculated under the discrete method, which treats the interim period as if it were the annual period and determines the income tax expense or benefit on that basis. The discrete method is applied when application of the estimated annual effective tax rate is impractical because it isnot possible to reliably estimate the annual effective tax rate. The Company believes, at this time, the use of the discrete method is more appropriate as the annual effective tax rate cannot be reliably estimated given the Company's full valuation allowance recorded on its deferred tax assets and annual utilization limitations that prevent the Company from fully offsetting its expected current income tax liabilities with its available net operating loss and income tax credits.

The effective tax rate for thethree months ended* March 31, 2025varies from thethree* months ended* March 31, 2024,primarily as a result of the Company's valuation allowance recorded against its net deferred tax assets and annual tax attribute limitations that result in current income tax expense. Income taxes paid during thethree* months ended* March 31, 2025and2024* were $8 and $0, respectively.

Note10 — Related-Party Transactions

Chief Executive Officer

The CEO has a partial interest in a company that the Company had partnered with for its EM-100/Alaway® Preservative Free eye allergy product as described below.

The Company acquired the exclusive rights to sell the EM-100 product in the United States pursuant to a Sales and Marketing Agreement (the “Eyemax Agreement”) dated* August 11, 2017,between the Company and Eyemax LLC (“Eyemax”), an entity affiliated with the Company’s CEO. Under the terms of the Eyemax Agreement, the Company would pay Eyemax $250 upon FDA approval, $500 upon thefirst* commercial sale of the product, and a royalty of 10% on the net sales of all products. The Eyemax Agreement was for an initial term often years from the date of the Eyemax Agreement, subject to successivetwo-year renewals unless the Company elected to terminate the Eyemax Agreement.

On* February 18, 2019,the Company entered into an Amended and Restated Agreement with Eyemax amending the Sales Agreement (the “Amended Agreement”). Pursuant to the Amended Agreement, Eyemax sold the Company all of its right, title and interest in EM-100, including any such product that incorporates or utilizes Eyemax’s intellectual property rights. Pursuant to the Amended Agreement, the Company paid Eyemaxtwo* milestone payments: (i)one milestone payment for $250 upon regulatory approval in the territory by the FDA of thefirst single agent product and (ii)one milestone payment for $500 following thefirst commercial sale of thefirst single agent product in the territory. From the effective date of the Amended Agreement, the Company has realized a total of $1,840 of the non-royalty and royalty revenue through* March 31, 2025*. The EM-100 asset and its associated product rights were sold to Bausch Health on* February 18, 2019,and future potential royalties oftwelve percent on Bausch Health sales of the product, named Alaway® Preservative Free by Bausch, which was approved by the FDA in September 2020,would be split between Eyemax and the Company. There wereno amounts due to Eyemax under the terms of the Amended Agreement as of March 31, 2025*, and Bausch Health discontinued sales of Alaway® Preservative Free effective* March 24, 2023.*

The CEO has a partial interest in a company that the Company has entered into an agreement with as described below.

Previously, the Company acquired DS-200 and all related intellectual property pursuant to an asset purchase agreement (the “Selenix Agreement”) dated* June 23, 2017between the Company and Selenix LLC (“Selenix”), an entity affiliated with the CEO. On August 30, 2024,the Company amended the Selenix Agreement in tandem with an agreement to sell DS-200 in August 2024 (see Note12*). Pursuant to the terms of the amended Selenix Agreement, Selenix waived its rights to future milestone payments and 50% of DS-200 profit in exchange for 45% of proceeds received by the Company from the DS-200 sale agreement. Selenix is 50% owned by Messa Holdings LLC (“Messa”), which is 100% owned by the CEO. As of* March 31, 2025*, the Company’s Condensed Balance Sheet reflected a $675 payment due to Selenix in accrued liabilities.

Note11 — Leases

The Company recognizes a right-of-use (“ROU”) asset and a lease liability on the balance sheet for substantially all leases, including operating leases, and separates lease components from non-lease components related to its office space lease.

In* June 2024,the Company renewed its office lease for atwo-year period through March 2027*and recorded $219 in ROU assets and$219 in operating lease liabilities in association with the lease extension.

The Company’s operating lease cost as presented as G&A in the Condensed Statements of Operations was$22 and$20, respectively. For thethree months ended* March 31, 2025and2024*, cash paid for amounts included in the measurement of operating lease liabilities was$23 and$10, respectively. The ROU asset non-cash lease expense for thethree months ended* March 31, 2025and2024* was$17 and$18, respectively, and is reflected within non-cash lease expense on the Company’s Condensed Statements of Cash Flows. As of* March 31, 2025*, the remaining lease term was 2.0 years andthe weighted average discount rate was 8.6%.

14

Note 11— Leases (continued)****

The table below presents the lease-related assets and liabilities recorded on the balance sheet as of* March 31, 2025* and* December 31, 2024* (in thousands).

The Company’s future lease commitments as of* March 31, 2025*, are as indicated below:

Note12 — Commitments and Contingencies

Legal

The Company is subject to legal proceedings and claims that* mayarise in the ordinary course of business. The Company isnot* aware of any pending or threatened litigation matters at this time that would have a material impact on the operations of the Company.

License and product development agreements

The Company has entered into various agreements which are described below.

In* March 2020,the Company entered into an Exclusive License and Supply Agreement (the “Alkindi License Agreement”) with Diurnal for marketing ALKINDI SPRINKLE® in the United States. In September 2020,ALKINDI SPRINKLE®’s New Drug Application (NDA) was approved by the FDA as a replacement therapy for pediatric patients with adrenocortical insufficiency. For the initial licensing milestone fee, the Company paid Diurnal $3,500 in cash and issued 379,474 shares of its common stock to Diurnal, which were valued at $1,264 based on the Company’s closing stock price of $3.33 on March 26, 2020**.* The Company paid Diurnal $1,000 for a2023 sales milestone in* January 2024that was recorded as licensing cost of sales in December 2023and could pay up to $44,000 in additional commercial net sales milestones. The Company will pay tiered royalties of 11.5% to 17.0% on net sales and could pay Diurnal$2,500* if the product obtains orphan drug exclusivity status from the FDA. In* December 2024,*the Company and Diurnal entered into an amendment to the Alkindi License Agreement to extend the agreement terms to incorporate both ALKINDI SPRINKLE® and ET-400 in the existing agreement terms.

In* June 2021,the Company acquired U.S. and Canadian rights to Crossject’s ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis. The Company paid Crossject$500* upon signing,$500 in* March 2022upon a completion of a successful technical batch and could pay up to$3,500* in additional development milestones and up to*$6,000* in commercial milestones, as well as a10% royalty on net sales.

In* March 2023,the Company acquired rare disease endocrinology product candidate ET-600 from Tulex. The Company paid $450 to Tulex in July 2023as a result of successful manufacturing of registration batches. The Company will pay Tulex $200 upon acceptance by the FDA of the NDA for the product, $250 uponfirst* commercial sale of the product, and tiered royalties of 12.5% to 17.0% on net sales.

In* March 2024,*the Company acquired the U.S. rights to PKU GOLIKE® from Relief Therapeutics Holding SA. The Company paid $2,200 and could pay up to $2,000 in additional commercial milestones. The Company will pay the seller a royalty of 30% of net sales, which will include the cost of the product.

In* August 2024**,* the Company entered into an agreement to sell its DS-200 product candidate. The Company received $500 upfront, and in* March 2025the Company recognized licensing revenue of $1,500 from a development milestone and the $1,500 is reflected in the Company's accounts receivable balance as of March 31, 2025.The Company could receive additional payments of up to $5,000 based on the achievement of certain future development and commercial milestones related to DS-200.* The Company will retain 45% of the proceeds from the transaction with the balance being distributed to other partners.

In* November 2024,the Company entered into a licensing agreement with AMMTeK. pursuant to which the Company has agreed to acquire the U.S. rights to Amglidia (glyburide oral suspension). Amglidia was approved by the European Medicines Agency in2018* and has been granted Orphan Drug Designation by the U.S. FDA. AMMTeK. has conducted a post-approval study trackingfive years of real-world safety and efficacy in European patients, which will be used to support the Company's s New Drug Application (“NDA”) submission. The Company intends to hold a meeting with the FDA in2025. Under the terms of the licensing agreement, the Company willnot make any upfront payments and retains the right to terminate the licensing agreement based on FDA meeting results prior to any payments being owed. The Company could pay up to $2,350 as follows: $500 following the receipt of FDA minutes; $550 upon NDA acceptance for review by FDA; and $1,300 upon NDA approval by the FDA andfirst commercial sale. The Company would also be required to pay a royalty of 14% of net sales to AMMTek.

15

Note12 — Commitments and Contingencies (continued)**

In* December 2024,the Company acquired GALZIN® (zinc acetate) from Teva Pharmaceuticals USA, Inc and assumed the commercialization of the product in the U.S. during Marchof2025.* The Company accounted for the purchase as a product acquisition and paid $7,000 and paid an additional $200 for product inventory. The Company will pay the seller a royalty of 10% of U.S. net sales through thetenth anniversary of the Company'sfirst commercial sales of the product in the U.S.

In* December 2024,the Company acquired INCRELEX® (mecasermin injection) from Ipsen S.A. The Company paid $22,500 and paid an additional $7,500 for product inventory. The Company will also make payments to seller of $2,500 on each of thefirst* andsecond anniversaries of closing. The Company determined that the asset purchase agreement met the definition of a business under ASC805; therefore, the Company accounted for the asset purchase agreement as a business combination and applied the acquisition method of accounting.

In* March 2025,the Company out-licensed the commercial rights to Increlex® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. (“Esteve”). Under the terms of the licensing agreement, Esteve will pay the Company€4,000 up front to license the rights to Increlex® for up toten* years, and Esteve is also receiving an option to acquire the international rights in the future for a purchase price of up to€6,000. In addition, the Company also entered into a supply agreement and will supply product to Esteve at a fixed transfer price. In accordance with the accounting pronouncement guidance in ASC606 with respect to the license and supply agreements between the Company and Esteve, the Company recognized as of and for thethree months ended* March 31, 2025,$4,327 in accounts receivable, licensing revenues of $1,786 and deferred revenues of $2,541. With respect to the $2,541 in deferred revenues, $330 and $2,211 are reflected in accrued liabilities and other long-term liabilities, respectively in the Company Condensed Balance Sheet as of March 31, 2025.*Deferred revenues will be amortized to licensing revenues over the course of the agreements based on quarterly Increlex® product sales, and at the end of the license agreement, a deferred revenue residual will be recognized at the end of the initial term of the license agreement.

Indemnification

As permitted under Delaware law and in accordance with the Company’s Amended and Restated Bylaws, the Company is required to indemnify its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors and officers. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company hasnot recorded any liabilities for these indemnification rights and agreements as of* March 31, 2025* or* December 31, 2024*.

Note13 — Subsequent Events

On* April 28, 2025,the Company submitted an NDA to the FDA for ET-600, the Company's proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The Company expects the application to be assigned a10*-month FDA review, allowing for potential approval and launch in thefirst quarter of2026.